Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Johnson & Johnson Taiwan Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT00744757
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Hussein Tawbi
- Target Recruit Count
- 39
- Registration Number
- NCT00715793
- Locations
- 🇺🇸
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Secondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00703300
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00701298
- Locations
- 🇺🇸
Nevada Cancer Institute-Summerlin Campus, Las Vegas, Nevada, United States
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 52
- Registration Number
- NCT00691938
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT00671697
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT00619099
- Locations
- 🇺🇸
Landmark Medical Center, Woonsocket, Rhode Island, United States
🇺🇸Sarah Cannon Research, Nashville, Tennessee, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2011-12-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00561912
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML
- Conditions
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 30
- Registration Number
- NCT00538876
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- Drug: decitabineOther: laboratory biomarker analysisOther: pharmacological studyOther: high performance liquid chromatographyGenetic: microarray analysisGenetic: RNA analysisOther: mass spectrometryGenetic: DNA methylation analysisOther: matrix-assisted laser desorption/ionization time of flight mass spectrometry
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00492401
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.